KOPRAN
|
KOPRAN Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 5.33 | 7.98 | 10.57 | 5.65 | 12.66 |
| CEPS(Rs) | 8.95 | 11.21 | 13.24 | 8.29 | 14.96 |
| DPS(Rs) | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| Book NAV/Share(Rs) | 109.54 | 107.02 | 101.68 | 91.11 | 88.40 |
| Tax Rate(%) | 25.10 | 25.79 | 24.56 | 24.49 | 25.37 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 9.09 | 11.58 | 12.10 | 9.28 | 18.00 |
| EBIT Margin(%) | 6.58 | 9.73 | 12.39 | 7.55 | 17.93 |
| Pre Tax Margin(%) | 5.04 | 8.25 | 10.99 | 6.46 | 16.88 |
| PAT Margin (%) | 3.78 | 6.12 | 8.29 | 4.88 | 12.60 |
| Cash Profit Margin (%) | 6.34 | 8.60 | 10.39 | 7.16 | 14.89 |
| Performance Ratios | |||||
| ROA(%) | 2.94 | 4.86 | 7.32 | 4.32 | 11.62 |
| ROE(%) | 4.92 | 7.66 | 10.96 | 6.29 | 18.19 |
| ROCE(%) | 6.65 | 9.75 | 13.78 | 8.30 | 21.40 |
| Asset Turnover(x) | 0.78 | 0.79 | 0.88 | 0.89 | 0.92 |
| Sales/Fixed Asset(x) | 1.78 | 2.21 | 2.47 | 2.53 | 2.66 |
| Working Capital/Sales(x) | 3.85 | 2.85 | 2.61 | 2.51 | 1.84 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.56 | 0.45 | 0.40 | 0.39 | 0.38 |
| Receivable days | 127.91 | 123.83 | 111.32 | 94.82 | 93.20 |
| Inventory Days | 89.35 | 89.24 | 79.90 | 91.76 | 94.14 |
| Payable days | 122.98 | 112.82 | 97.72 | 81.67 | 108.83 |
| Valuation Parameters | |||||
| PER(x) | 20.25 | 21.93 | 24.45 | 19.55 | 22.24 |
| PCE(x) | 12.06 | 15.61 | 19.51 | 13.33 | 18.82 |
| Price/Book(x) | 0.99 | 1.64 | 2.54 | 1.21 | 3.19 |
| Yield(%) | 2.78 | 1.71 | 1.16 | 2.72 | 1.07 |
| EV/Net Sales(x) | 0.98 | 1.54 | 2.17 | 1.08 | 2.88 |
| EV/Core EBITDA(x) | 10.70 | 12.58 | 14.95 | 10.85 | 14.03 |
| EV/EBIT(x) | 14.87 | 15.78 | 17.48 | 14.12 | 15.82 |
| EV/CE(x) | 0.98 | 1.45 | 2.25 | 1.16 | 2.25 |
| M Cap / Sales | 0.76 | 1.34 | 2.03 | 0.97 | 2.84 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 8.23 | 2.44 | 11.54 | 15.38 | -2.91 |
| Core EBITDA Growth(%) | -18.97 | -13.64 | 62.27 | -44.02 | -1.77 |
| EBIT Growth(%) | -26.86 | -19.50 | 80.64 | -51.50 | -2.99 |
| PAT Growth(%) | -33.26 | -24.34 | 87.11 | -55.38 | -0.93 |
| EPS Growth(%) | -33.25 | -24.46 | 87.11 | -55.38 | -11.13 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.29 | 0.29 | 0.20 | 0.17 | 0.17 |
| Current Ratio(x) | 1.51 | 1.76 | 2.08 | 2.25 | 2.74 |
| Quick Ratio(x) | 1.04 | 1.18 | 1.44 | 1.52 | 1.75 |
| Interest Cover(x) | 4.28 | 6.56 | 8.86 | 6.93 | 16.98 |
| Total Debt/Mcap(x) | 0.29 | 0.17 | 0.08 | 0.14 | 0.05 |
Compare Financial Ratios of peers of KOPRAN
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| KOPRAN | ₹876.2 Cr | -3.9% | -4% | 18.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,630.0 Cr | -0.1% | 0.5% | 14% | Stock Analytics | |
| DIVIS LABORATORIES | ₹218,972.0 Cr | -0.9% | 21.1% | 25.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,358.0 Cr | -1.3% | 1.1% | 32.7% | Stock Analytics | |
| CIPLA | ₹118,916.0 Cr | 0.2% | 2.1% | -5.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,824.0 Cr | 0.2% | -7.7% | -7.5% | Stock Analytics | |
KOPRAN Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| KOPRAN | -3.9% |
-4% |
18.2% |
| SENSEX | 0.5% |
2.6% |
-3.7% |
You may also like the below Video Courses
